Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03502616 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 270
- Enrollment target
NCT03502616: Completed Phase 3 study, sponsored by Pfizer.
NCT03502616 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 270 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03502616, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 270 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
Primary Outcome
ASAS20 assess 4 domains: Patient Global Assessment of Disease (PGA) (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of
Interventions
- DRUG Tofacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2020-08-20 |
| Phase | Phase 3 |
What the finished NCT03502616 record still lists
NCT03502616 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which Tofacitinib is the first listed.
NCT03502616 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03502616 about?
NCT03502616 is a clinical study titled "Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)". The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
What is the current status of trial NCT03502616?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 270 participants. The study started on 2018-06-07. Estimated completion is 2020-08-20.
What interventions are being tested in trial NCT03502616?
The interventions under investigation include: Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT03502616?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03502616's enrollment target sits among peer trials
270 1217th of 2000 higher than 781 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI